期刊文献+

西黄丸含药血清通过P糖蛋白途径逆转肝癌细胞多药耐药的体外研究 被引量:9

In vitro study on the reversal effect of serum containing Xihuang pill on the multidrug-resistance of hepatic cancer cells via P-glytoprotein pathway
原文传递
导出
摘要 [目的]探讨西黄丸含药血清对多药耐药人肝癌细胞株BEL-7404/Adr细胞和HepG2/Adr细胞耐阿霉素作用的影响及机理。[方法]制备西黄丸含药血清;BEL-7404/Adr细胞和HepG2/Adr细胞分别用西黄丸含药血清、阿霉素及二者联合处理;MTT法检测细胞增殖;Annexin V-FITC/PI双染色流式细胞术检测细胞凋亡;荧光酶标仪测定细胞内阿霉素的荧光强度;Western-blot法检测细胞P-糖蛋白(P-gp)的表达。[结果]西黄丸含药血清联合不同浓度阿霉素处理24h后,BEL-7404/Adr细胞和HepG2/Adr细胞增殖抑制率和凋亡率高于单用同浓度阿霉素组,比较差异有统计学意义(P<0.05);西黄丸含药血清联合不同浓度阿霉素处理12h后,BEL-7404/Adr细胞和HepG2/Adr细胞内阿霉素的荧光强度高于单用同浓度阿霉素组,比较差异有统计学意义(P<0.05);西黄丸含药血清处理12h后,BEL-7404/Adr细胞和HepG2/Adr细胞P-gp蛋白表达水平降低,较对照组差异有统计学意义(P<0.05)。[结论]西黄丸含药血清显著逆转BEL-7404/Adr细胞和HepG2/Adr细胞的耐阿霉素作用,其机制可能与西黄丸含药血清下调细胞多药耐药蛋白P-gp表达相关。 [Objective]To investigate the reversal effects and mechanisms of serum containing Xihuang pill on adriamycin resistance of the multidrug-resistant hepatic cancer cells including the human hepatocellular carcinoma BEL-7404/Adr cell and HepG2/Adr cell.[Methods]Serum containing Xihuang pill was prepared.BEL-7404/Adr cell and HepG2/Adr cell were treated with serum containing Xihuang pill,adriamycin,or their combinations.The proliferation and apoptosis of cells were analyzed by MTT assay and flow cytometry(AnnexinV-FITC/PI double staining assay).Intracellular accumulation of adriamycin was measured by the detection of fluorescence intensity of cell lysates using microplate reader.The protein expres-sions of P-gp was detected by Western blot.[Results]The growth inhibition rate and apoptosis rate of the BEL-7404/Adr cell and HepG2/Adr cell treated with the combination of serum containing Xihuang pill and adriamycin were higher compared with the cells treated with adriamycin alone(P0.05).Intracellular accumulation of adriamycin was significantly enhanced and the protein expression of P-gp decreased by the treatment of serum containing Xihuang pill(P0.05).[Conclusion]Serum containing Xihuang pill reverses the multidrug-resistance of the human hepatocellular carcinoma BEL-7404/Adr cell and HepG2/Adr cell,and the P-glytoprotein pathway may be involved in the effect.
出处 《中国中西医结合消化杂志》 CAS 2016年第2期83-86,91,共5页 Chinese Journal of Integrated Traditional and Western Medicine on Digestion
基金 安徽高校省级自然科学研究重点项目(No:KJ2012A163)
关键词 西黄丸 多药耐药 肝细胞癌 P糖蛋白 Xihuang pill Multidrug-resistance hepatocellular carcinoma P-glytoprotein
  • 相关文献

参考文献6

二级参考文献19

  • 1崔玲,晏卫东,高天文.中药血清药理研究方法回顾与展望[J].武警医学,2004,15(6):460-461. 被引量:9
  • 2王筠,张军平.中药血清药理学实验方法研究概况[J].天津中医药,2005,22(1):86-88. 被引量:29
  • 3阮建新,郭智,李小梅等.来曲唑治疗乳腺癌引起肝损害[J].药物不良反应杂志,2012,10(31):299-300.
  • 4国际妇产科联盟.妇科肿瘤FOG02分期[J].国际妇产科杂志,2009,36(5):5-6.
  • 5郭仁轩.乳腺外科学[M].北京:人民卫生出版社,2001:270-282.
  • 6孙燕.临床肿瘤手册[J].川白床合理用药杂志,2013,6(4):153-154.
  • 7梁文波,张学梅,宋旦旨.西黄丸含药血清对乳腺癌细胞生长的影响[J].时珍国医国药,2012,33(30):6691-6692.
  • 8Zhou M M,Yang K,Jiang Y P. Study on the methods of Chinese herbs' serum pharmacology:the effects of drug serum keep in low temperature and inactivation[J].Pharmacy and Clinics of Chinese Materia Medica,1999,(02):44-46.
  • 9葛金文,朱惠斌,王宇红,贺蓉,贺石林.关于中药血清药理学方法的再思考[J].世界科学技术-中医药现代化,2008,10(6):16-22. 被引量:22
  • 10陈信义,王婧,张雅月,董青.西黄丸药效学研究及治疗肿瘤特点分析[J].中华中医药杂志,2010,25(3):409-412. 被引量:43

共引文献82

同被引文献201

引证文献9

二级引证文献99

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部